Clarice Gareri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Clarice Gareri has a total of 96 co-authors. Here are the top co-authors by number of shared publications:
- Ciro Indolfi
Italian Federation of Cardiology, Roma, Italy
13 shared publications - Salvatore De Rosa
Department of Medical and Surgical Sciences, Magna Graecia University, 88100 Catanzaro, Italy
10 shared publications - Alberto Polimeni
Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy
8 shared publications Claudio Iaconetti
Division of Cardiology, Department of Medical and Surgical Sciences, Magna Graecia University, Italy
7 shared publications- Antonio Curcio
Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy
6 shared publications - Jolanda Sabatino
Department of Medical and Surgical Sciences, Magna Graecia University, 88100 Catanzaro, Italy
5 shared publications
Latest Publications
- 13 August 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 17 (849) , eadk5736
Phosphorylation patterns in the AT1R C-terminal tail specify distinct downstream signaling pathways
Different ligands stabilize specific conformations of the angiotensin II type 1 receptor (AT1R) that direct distinct signaling cascades mediated by heterotrimeric G proteins or β-arrestin. These different active conformations are thought to engage distinct intracellular transducers because of differential phosphorylation patterns in the receptor C-terminal tail (the “barcode” hypothesis). Here, we identified the AT1R barcodes for the endogenous agonist AngII, which stimulates both G protein activation and β-arrestin recruitment, and for a synthetic biased agonist that only stimulates β-arrestin recruitment. The endogenous and β-arrestin–biased agonists induced two different ensembles of phosphorylation sites along the C-terminal tail. The phosphorylation of eight serine and threonine residues in the proximal and middle portions of the tail was required for full β-arrestin functionality, whereas phosphorylation of the serine and threonine residues in the distal portion of the tail had little influence on β-arrestin function. Similarly, molecular dynamics simulations showed that the proximal and middle clusters of phosphorylated residues were critical for stable β-arrestin–receptor interactions. These findings demonstrate that ligands that stabilize different receptor conformations induce different phosphorylation clusters in the C-terminal tail as barcodes to evoke distinct receptor-transducer engagement, receptor trafficking, and signaling.
- 13 August 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 17 (849) , eadk5736
Phosphorylation patterns in the AT1R C-terminal tail specify distinct downstream signaling pathways
Different ligands stabilize specific conformations of the angiotensin II type 1 receptor (AT1R) that direct distinct signaling cascades mediated by heterotrimeric G proteins or β-arrestin. These different active conformations are thought to engage distinct intracellular transducers because of differential phosphorylation patterns in the receptor C-terminal tail (the “barcode” hypothesis). Here, we identified the AT1R barcodes for the endogenous agonist AngII, which stimulates both G protein activation and β-arrestin recruitment, and for a synthetic biased agonist that only stimulates β-arrestin recruitment. The endogenous and β-arrestin–biased agonists induced two different ensembles of phosphorylation sites along the C-terminal tail. The phosphorylation of eight serine and threonine residues in the proximal and middle portions of the tail was required for full β-arrestin functionality, whereas phosphorylation of the serine and threonine residues in the distal portion of the tail had little influence on β-arrestin function. Similarly, molecular dynamics simulations showed that the proximal and middle clusters of phosphorylated residues were critical for stable β-arrestin–receptor interactions. These findings demonstrate that ligands that stabilize different receptor conformations induce different phosphorylation clusters in the C-terminal tail as barcodes to evoke distinct receptor-transducer engagement, receptor trafficking, and signaling.
- Open Access
- 4 July 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (13) , 3884
Antisense Oligonucleotides and Small Interfering RNA for the Treatment of Dyslipidemias
The burden of atherosclerotic disease worldwide necessitates implementing the treatment of its risk factors. Among them, hypercholesterolemia has a central role. In addition to conventional small organic compounds and the recently introduced monoclonal antibodies, new technologies are arising such as the antisense oligonucleotides and small interfering RNAs (siRNAs) that operate upstream, blocking the mRNA translation of the proteins specifically involved in lipid metabolism. In this review, we briefly explain the mechanisms of action of these molecules and discuss the difficulties related to their in vivo use as therapeutical agents. We go over the oligonucleotides tested in clinical trials that could potentially revolutionize the care of patients by acting on proteins involved in the lipoprotein metabolism and regulation, namely: angiopoietin-like protein 3 (ANGPTL3); lipoprotein a (Lp(a)); apolipoprotein B (Apo B); apolipoprotein C III (Apo C-III); and proprotein convertase subtilisin–kexin type 9 (PCSK9). Finally, the differences between ASOs and siRNAs, their future possible clinical applications, and the role of Inclisiran, a siRNA direct against PCSK9 to reduce LDL-C, were reviewed in detail.
- 4 July 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (13) , 3884
Open AccessAntisense Oligonucleotides and Small Interfering RNA for the Treatment of Dyslipidemias
The burden of atherosclerotic disease worldwide necessitates implementing the treatment of its risk factors. Among them, hypercholesterolemia has a central role. In addition to conventional small organic compounds and the recently introduced monoclonal antibodies, new technologies are arising such as the antisense oligonucleotides and small interfering RNAs (siRNAs) that operate upstream, blocking the mRNA translation of the proteins specifically involved in lipid metabolism. In this review, we briefly explain the mechanisms of action of these molecules and discuss the difficulties related to their in vivo use as therapeutical agents. We go over the oligonucleotides tested in clinical trials that could potentially revolutionize the care of patients by acting on proteins involved in the lipoprotein metabolism and regulation, namely: angiopoietin-like protein 3 (ANGPTL3); lipoprotein a (Lp(a)); apolipoprotein B (Apo B); apolipoprotein C III (Apo C-III); and proprotein convertase subtilisin–kexin type 9 (PCSK9). Finally, the differences between ASOs and siRNAs, their future possible clinical applications, and the role of Inclisiran, a siRNA direct against PCSK9 to reduce LDL-C, were reviewed in detail.
- Open Access
- 1 January 2020
- Published by SAGE Publications in Sage Open Medical Case Reports
- Vol. 8
Use of a new cold plasma tool for psoriasis treatment: A case report
Cold atmospheric plasma sources are emerging as new potent tools in different fields of medicine, from oncology to dermatology. Psoriasis is a chronic inflammatory disease characterized by the presence of itchy red plaque on skin, known as psoriatic plaques. In this case report, we evaluate the effectiveness of a cold atmospheric plasma treatment on a psoriatic plaque on the hand of a 20-year-old woman. Two quick applications of the procedure led to a complete disappearance of the cutaneous lesion in 14 days. The results of this case show a potential application of this new technique in the dermatological field, as palmo-plantar psoriasis is usually resistant to traditional treatments. A clinical trial would be necessary in order to evaluate the real effectiveness of this plasma.
- 1 January 2020
- Published by SAGE Publications in Sage Open Medical Case Reports
- Vol. 8
Open AccessUse of a new cold plasma tool for psoriasis treatment: A case report
Cold atmospheric plasma sources are emerging as new potent tools in different fields of medicine, from oncology to dermatology. Psoriasis is a chronic inflammatory disease characterized by the presence of itchy red plaque on skin, known as psoriatic plaques. In this case report, we evaluate the effectiveness of a cold atmospheric plasma treatment on a psoriatic plaque on the hand of a 20-year-old woman. Two quick applications of the procedure led to a complete disappearance of the cutaneous lesion in 14 days. The results of this case show a potential application of this new technique in the dermatological field, as palmo-plantar psoriasis is usually resistant to traditional treatments. A clinical trial would be necessary in order to evaluate the real effectiveness of this plasma.
- Open Access
- 17 December 2019
- Published by MDPI AG in Applied Sciences
- Vol. 9 (24) , 5560
The Role of Thermal Effects in Plasma Medical Applications: Biological and Calorimetric Analysis
Plasma Medicine tools exploit the therapeutic effects of the exposure of living matter to plasma produced at atmospheric pressure. Since these plasmas are usually characterized by a non-thermal equilibrium (highly energetic electrons, low temperature ions), thermal effects on the substrate are usually considered negligible. Conversely, reactive oxygen and nitrogen species (RONS), UV radiation and metastables are thought to play a major role. In this contribution, we compare the presence of thermal effects in different operational regimes (corresponding to different power levels) of the Plasma Coagulation Controller (PCC), a plasma source specifically designed for accelerating blood coagulation. In particular, we analyze the application of PCC on human blood samples (in vitro) and male Wistar rats tissues (in vivo). Histological analysis points out, for the highest applied power regime, the onset of detrimental thermal effects such as red cell lysis in blood samples and tissues damages in in-vivo experiments. Calorimetric bench tests performed on metallic targets show that the current coupled by the plasma on the substrate induces most of measured thermal loads through a resistive coupling. Furthermore, the distance between the PCC nozzle and the target is found to strongly affect the total power.
- 17 December 2019
- Published by MDPI AG in Applied Sciences
- Vol. 9 (24) , 5560
Open AccessThe Role of Thermal Effects in Plasma Medical Applications: Biological and Calorimetric Analysis
Plasma Medicine tools exploit the therapeutic effects of the exposure of living matter to plasma produced at atmospheric pressure. Since these plasmas are usually characterized by a non-thermal equilibrium (highly energetic electrons, low temperature ions), thermal effects on the substrate are usually considered negligible. Conversely, reactive oxygen and nitrogen species (RONS), UV radiation and metastables are thought to play a major role. In this contribution, we compare the presence of thermal effects in different operational regimes (corresponding to different power levels) of the Plasma Coagulation Controller (PCC), a plasma source specifically designed for accelerating blood coagulation. In particular, we analyze the application of PCC on human blood samples (in vitro) and male Wistar rats tissues (in vivo). Histological analysis points out, for the highest applied power regime, the onset of detrimental thermal effects such as red cell lysis in blood samples and tissues damages in in-vivo experiments. Calorimetric bench tests performed on metallic targets show that the current coupled by the plasma on the substrate induces most of measured thermal loads through a resistive coupling. Furthermore, the distance between the PCC nozzle and the target is found to strongly affect the total power.
- 1 March 2019
- Published by Elsevier in Vascular Pharmacology
- Vol. 114, 49-63
Non-coding RNAs in vascular remodeling and restenosis
- 1 March 2019
- Published by Elsevier in Vascular Pharmacology
- Vol. 114, 49-63
Non-coding RNAs in vascular remodeling and restenosis
- Open Access
- 1 February 2019
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 294 (7) , 2500-2518
The deubiquitinase ubiquitin–specific protease 20 is a positive modulator of myocardial β1-adrenergic receptor expression and signaling
- 1 February 2019
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 294 (7) , 2500-2518
Open AccessThe deubiquitinase ubiquitin–specific protease 20 is a positive modulator of myocardial β1-adrenergic receptor expression and signaling
- Top Cited PapersOpen Access
- 31 August 2018
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 123 (6) , 716-735
G-Protein–Coupled Receptors in Heart Disease
GPCRs (G-protein [guanine nucleotide-binding protein]–coupled receptors) play a central physiological role in the regulation of cardiac function in both health and disease and thus represent one of the largest class of surface receptors targeted by drugs. Several antagonists of GPCRs, such as βARs (β-adrenergic receptors) and Ang II (angiotensin II) receptors, are now considered standard of therapy for a wide range of cardiovascular disease, such as hypertension, coronary artery disease, and heart failure. Although the mechanism of action for GPCRs was thought to be largely worked out in the 80s and 90s, recent discoveries have brought to the fore new and previously unappreciated mechanisms for GPCR activation and subsequent downstream signaling. In this review, we focus on GPCRs most relevant to the cardiovascular system and discuss traditional components of GPCR signaling and highlight evolving concepts in the field, such as ligand bias, β-arrestin–mediated signaling, and conformational heterogeneity.
- 31 August 2018
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 123 (6) , 716-735
Top Cited PapersOpen AccessG-Protein–Coupled Receptors in Heart Disease
GPCRs (G-protein [guanine nucleotide-binding protein]–coupled receptors) play a central physiological role in the regulation of cardiac function in both health and disease and thus represent one of the largest class of surface receptors targeted by drugs. Several antagonists of GPCRs, such as βARs (β-adrenergic receptors) and Ang II (angiotensin II) receptors, are now considered standard of therapy for a wide range of cardiovascular disease, such as hypertension, coronary artery disease, and heart failure. Although the mechanism of action for GPCRs was thought to be largely worked out in the 80s and 90s, recent discoveries have brought to the fore new and previously unappreciated mechanisms for GPCR activation and subsequent downstream signaling. In this review, we focus on GPCRs most relevant to the cardiovascular system and discuss traditional components of GPCR signaling and highlight evolving concepts in the field, such as ligand bias, β-arrestin–mediated signaling, and conformational heterogeneity.
- Open Access
- 15 January 2018
- Published by Springer Nature in Scientific Reports
- Vol. 8 (1) , 1-12
Hindlimb Ischemia Impairs Endothelial Recovery and Increases Neointimal Proliferation in the Carotid Artery
Peripheral ischemia is associated with higher degree of endothelial dysfunction and a worse prognosis after percutaneous coronary interventions (PCI). However, the role of peripheral ischemia on vascular remodeling in remote districts remains poorly understood. Here we show that the presence of hindlimb ischemia significantly enhances neointima formation and impairs endothelial recovery in balloon-injured carotid arteries. Endothelial-derived microRNAs are involved in the modulation of these processes. Indeed, endothelial miR-16 is remarkably upregulated after vascular injury in the presences of hindlimb ischemia and exerts a negative effect on endothelial repair through the inhibition of RhoGDIα and nitric oxide (NO) production. We showed that the repression of RhoGDIα by means of miR-16 induces RhoA, with consequent reduction of NO bioavailability. Thus, hindlimb ischemia affects negative carotid remodeling increasing neointima formation after injury, while systemic antagonizzation of miR-16 is able to prevent these negative effects.
- 15 January 2018
- Published by Springer Nature in Scientific Reports
- Vol. 8 (1) , 1-12
Open AccessHindlimb Ischemia Impairs Endothelial Recovery and Increases Neointimal Proliferation in the Carotid Artery
Peripheral ischemia is associated with higher degree of endothelial dysfunction and a worse prognosis after percutaneous coronary interventions (PCI). However, the role of peripheral ischemia on vascular remodeling in remote districts remains poorly understood. Here we show that the presence of hindlimb ischemia significantly enhances neointima formation and impairs endothelial recovery in balloon-injured carotid arteries. Endothelial-derived microRNAs are involved in the modulation of these processes. Indeed, endothelial miR-16 is remarkably upregulated after vascular injury in the presences of hindlimb ischemia and exerts a negative effect on endothelial repair through the inhibition of RhoGDIα and nitric oxide (NO) production. We showed that the repression of RhoGDIα by means of miR-16 induces RhoA, with consequent reduction of NO bioavailability. Thus, hindlimb ischemia affects negative carotid remodeling increasing neointima formation after injury, while systemic antagonizzation of miR-16 is able to prevent these negative effects.
- 4 January 2018
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
- Vol. 20 (6) , 1000-1010
Transcoronary Concentration Gradients of Circulating microRNAs in Heart Failure
Circulating levels of microRNAs (miRNAs) are emergent promising biomarkers for cardiovascular disease. Altered expression of miRNAs has been related to heart failure (HF) and cardiac remodelling. We measured the concentration gradients across the coronary circulation to assess their usefulness to diagnose HF of different aetiologies. Circulating miRNAs were measured in plasma samples simultaneously obtained from the aorta and the coronary venous sinus in patients with non-ischaemic HF (NICM-HF, n = 23) ischaemic HF (ICM-HF, n = 41), and in control patients (n = 11). A differential modulation of circulating levels of miR-423, -34a, -21-3p, -126, -199 and -30a was found across the aetiology groups. Interestingly, a positive transcoronary gradient was found for miR-423 (P < 0.001) and miR-34a (P < 0.001) only in the ICM-HF group. On the contrary, a positive gradient was found for miR-21-3p (P < 0.001) and miR-30a (P = 0.030) only in the NICM-HF group. Finally, no significant variations were observed in the transcoronary gradient of miR-126 or miR-199. The present findings suggest that circulating levels of miRNAs are differentially expressed in patients with HF of different aetiologies. The presence of a transcoronary concentration gradient suggests a selective release of miRNAs by the failing heart into the coronary circulation. The presence of aetiology-specific transcoronary concentration gradients in HF patients might provide important information to better understand their role in HF, and suggests they could be useful biomarkers to distinguish HF of different aetiologies.
- 4 January 2018
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
- Vol. 20 (6) , 1000-1010
Transcoronary Concentration Gradients of Circulating microRNAs in Heart Failure
Circulating levels of microRNAs (miRNAs) are emergent promising biomarkers for cardiovascular disease. Altered expression of miRNAs has been related to heart failure (HF) and cardiac remodelling. We measured the concentration gradients across the coronary circulation to assess their usefulness to diagnose HF of different aetiologies. Circulating miRNAs were measured in plasma samples simultaneously obtained from the aorta and the coronary venous sinus in patients with non-ischaemic HF (NICM-HF, n = 23) ischaemic HF (ICM-HF, n = 41), and in control patients (n = 11). A differential modulation of circulating levels of miR-423, -34a, -21-3p, -126, -199 and -30a was found across the aetiology groups. Interestingly, a positive transcoronary gradient was found for miR-423 (P < 0.001) and miR-34a (P < 0.001) only in the ICM-HF group. On the contrary, a positive gradient was found for miR-21-3p (P < 0.001) and miR-30a (P = 0.030) only in the NICM-HF group. Finally, no significant variations were observed in the transcoronary gradient of miR-126 or miR-199. The present findings suggest that circulating levels of miRNAs are differentially expressed in patients with HF of different aetiologies. The presence of a transcoronary concentration gradient suggests a selective release of miRNAs by the failing heart into the coronary circulation. The presence of aetiology-specific transcoronary concentration gradients in HF patients might provide important information to better understand their role in HF, and suggests they could be useful biomarkers to distinguish HF of different aetiologies.
- 1 January 2018
- Published by Begell House Inc. Publishers in Plasma Medicine
- Vol. 8 (3) , 245-254
Plasma Coagulation Controller: A Low- Power Atmospheric Plasma Source for Accelerated Blood Coagulation
In this contribution we present the main features of the Plasma Coagulation Controller (PCC) device, a cold atmospheric pressure plasma source based on the Dielectric Barrier Discharge (DBD) scheme, specifically designed for accelerating blood coagulation. The device is controlled by a microcontroller and can explore different operational parameters in terms of discharge repetition rate (1-20 kHz) and applied voltage (2-8 kV). Helium is used as a working gas. Effective current measured on a metallic target is of the order of 1 mA and, thus, suitable for application on human body. Emission spectroscopy analysis is performed: the presence in the plasma of reactive oxygen and nitrogen species (ROS and RONS) is highlighted in the different operational regimes. We present the results of multiple tests using the device in different biological processes, including reactive species production, bacterial removal, and in-vitro blood coagulation. Interestingly, tests on blood samples exposed to the helium plasma at different time points show a significant reduction of the coagulation compared to control samples.
- 1 January 2018
- Published by Begell House Inc. Publishers in Plasma Medicine
- Vol. 8 (3) , 245-254
Plasma Coagulation Controller: A Low- Power Atmospheric Plasma Source for Accelerated Blood Coagulation
In this contribution we present the main features of the Plasma Coagulation Controller (PCC) device, a cold atmospheric pressure plasma source based on the Dielectric Barrier Discharge (DBD) scheme, specifically designed for accelerating blood coagulation. The device is controlled by a microcontroller and can explore different operational parameters in terms of discharge repetition rate (1-20 kHz) and applied voltage (2-8 kV). Helium is used as a working gas. Effective current measured on a metallic target is of the order of 1 mA and, thus, suitable for application on human body. Emission spectroscopy analysis is performed: the presence in the plasma of reactive oxygen and nitrogen species (ROS and RONS) is highlighted in the different operational regimes. We present the results of multiple tests using the device in different biological processes, including reactive species production, bacterial removal, and in-vitro blood coagulation. Interestingly, tests on blood samples exposed to the helium plasma at different time points show a significant reduction of the coagulation compared to control samples.